Emerging infectious diseases include both new and existing ones
that are rapidly increasing in incidence or geographic range. Fifty
years ago when vaccines were introduced, it was optimisticly thought
that infectious disease problems had been solved. This resulted
in a period of complacency and reduced vigilance, which was followed
by the emergence of new catastrophic diseases such as influenza,
AIDS, SARS and Avian flu. These catastrophes diseases have raised
international awareness resulting in increased preparedness for
a quick response. As developing appropriate vaccines and therapies
is a lengthy process, deployment of other innovative methods of
killing viruses such as ViroForce is critically important.
Clostridium difficile
Clostridium difficile, commonly called C. difficile, is a bacterium
that causes diarrhea and other serious intestinal conditions. It
is the most common cause of infectious diarrhea in hospitals and
long-term care facilities in the industrialized world. The Avon
study in England calculated that Norovirus and C. difficile cost
a hospital US$2.38 million per annum. Based on studies such as these
it is calculated the aggregated cost of these two diseases in hospitals
in Canada, the US and the UK is US$21.126 billion per annum. And
these costs do not include those associated with MSRA.
Swine Flu H1N1
The latested data from World Health Organisation, WHO, September
25th 2009, evidences 300,000 lab H1N1 reported cases with close
to 4000 deaths in 191 countires.
MRSA (Methicillin-resistant Staphylococcus Aureus)
This is a bacterium that lives on the skin and the nose of about
25% of the population. Normally, this bacterium can cause infections
such as boils and abscesses. In hospitals it causes more serious
infections that can be both debilitating and sometimes lethal. Some
strains such as EMSRA spread very easily. In England there have
been sixteen strains of EMSRA identified, with an increase of 25%
from 1990 to 41% in 2003. In the US there is a high degree of MRSA
(20%) relative to Europe. The table below shows how devastating
MRSA can be to hospital patients, with 2X the mortality and length
of hospital stay associated with antibiotic resistance infections.
Surgical Site Infections in Canadian Hospitals
Outcome |
Uninfected
(N=193) |
MSSA
(NN=165) |
MRSA
(N=121) |
P value |
Death (%) |
2.1 |
6.7 |
20.7 |
<0.001 |
Hospital (days) |
5 |
14 |
23 |
<0.001 |
Median cost ($) |
29,455 |
52,791 |
92,363 |
<0.001 |
A review of 175 reported outbreaks of infection due to antimicrobial
resistance or susceptible bacteria (S. aureus, Salmonella, Shigella,
Serratia).
Current Disinfection Solutions
The present technology used by the health care and cruise ship
industries to fight these diseases employs a manual cleaning
process in conjunction with disinfecting liquids such as accelerated
H²O². This is a physical cleaning process that is labour
intensive, low-tech and often unreliable because it is not uniform
in its application. The increasing frequency of infectious disease
outbreaks requires a new and innovative solution to the problem. |